Should members of the Interagency Pain Research Coordinating Committee (IPRCC) with financial ties to the pharmaceutical industry be allowed to continue to serve? Perhaps not, according to U.S. Sen. Ron Wyden (D-Ore.), who is alarmed about potential conflicts of interest on the panel.
As the highest-ranking Democrat on the Senate Finance Committee, Sen. Wyden drafted a letter dated Feb. 5 to Health & Human Services (HHS)Secretary Sylvia Mathews Burwell, outlining his concerns.
Concerns